The old claim a dormant shell company was supposed to have buried

The situation

Six weeks before the planned listing date, a demand letter arrived addressed to a shell company that Ama and Meron's advisors believed had settled its only outstanding legal dispute years before either of them had ever heard of it. The letter came from Hanna, who had held a claim against the shell's previous, unrelated mining business over unpaid amounts from a supply arrangement that had ended badly. According to Hanna's new lawyer, that claim had never actually been released, and it was still sitting there, attached to the shell, waiting for whoever ended up controlling it next.

To understand why that mattered, it helps to go back to how Ama and Meron ended up needing that shell at all. Ama ran a physiotherapy-led clinic group with several locations north of Toronto; Meron ran a competing group built around optometry and vision care, serving much of the same patient base in the same region. The two businesses had spent years pulling patients and staff from each other before Ama and Meron, who had known each other professionally for a decade, concluded they would do better combined than competing. Rather than one company acquiring the other outright, they structured the combination as a reverse takeover: their two businesses would merge into a dormant public shell, a company with no active operations left but with an existing stock exchange listing, giving the combined clinic group public status quickly without the time and cost of a fresh public offering.

The shell had once operated a small mining exploration business that folded years earlier, leaving it as an empty public listing with a modest cash balance and, in theory, a clean legal history. Diligence early in the deal had turned up the old dispute with Hanna and a settlement agreement on file that appeared to resolve it. Ama and Meron's advisors treated the matter as closed and priced the combined transaction at roughly forty-two million dollars, on the assumption that the shell was bringing nothing but its listing and its cash to the deal.

The letter six weeks before closing said otherwise. If Hanna's claim really was still live, it would not stay with the empty shell after the reverse takeover closed. It would transfer directly onto the newly merged, fully operating clinic business, becoming a liability of the company Ama and Meron were about to spend years building together.

What the review found

We went back to the original settlement file rather than relying on the summary that earlier diligence had produced. What it showed was that the shell and Hanna had reached an agreement in principle years earlier, on paper terms that looked complete, but the release, the document that actually extinguishes a claim once it is signed, had never been executed by an authorized signatory of the shell. The person who had signed it had left their role with the company months before the signature, without formal authority to bind it, and no one had caught the gap at the time because the shell's own operations were already winding down and nobody was paying close attention.

That meant the settlement had produced a document that read like a release but did not function as one. Hanna's original claim, for unpaid amounts tied to the old mining business's supply arrangement, remained technically unresolved the entire time, sitting dormant simply because Hanna had not pursued it. Nothing in the intervening years had extinguished it; the passage of time alone does not release a claim, it only affects how long a party generally has to bring one, and Hanna's new lawyer had evidently concluded there was still time.

The review also clarified how a reverse takeover actually treats a target's pre-existing liabilities. In a share-based combination of this kind, the surviving public company is generally the same legal entity as the shell, carrying forward the shell's obligations along with its listing, unless those obligations are specifically addressed before the transaction closes. Ama and Meron's businesses were merging into that shell's corporate shell, not acquiring a clean slate; anything the shell owed, it would still owe afterward, only now inside a company with real assets and real revenue for a creditor to pursue.

Finally, the review confirmed the amount at stake was not trivial but was containable: Hanna's original claim, adjusted for the years since, sat in the low hundreds of thousands of dollars, small relative to the overall transaction value but large enough, and public enough once litigated, to complicate a newly listed company's first months of operation if it surfaced as active litigation rather than a resolved matter.

One detail mattered for how the fix would work. Because the defect sat in the release document itself rather than in the underlying claim, there was no straightforward way to argue the claim had simply expired or been abandoned through inaction. Hanna had not been sitting on a stale grievance out of neglect; Hanna's side had reasonably believed, the same way Ama and Meron's advisors had, that the matter was closed, until someone finally checked the signature against the shell's own records of who actually had authority to bind it at the time. That meant the resolution could not rest on a technical argument about delay. It had to be a genuine settlement, negotiated and properly executed this time.

What we did

1. Confirmed the defect in the original release with the shell's corporate records. Before treating the claim as live, we verified the signing authority gap directly against the shell's minute book and historical officer appointments, so the conclusion rested on documented fact rather than Hanna's lawyer's characterization of events, and so we could tell Ama and Meron with confidence what they were actually dealing with before any negotiating position was taken.
2. Assessed whether the transaction timeline could simply absorb a delay. The listing date had been set around Ama and Meron's own operational plans for combining their clinics' billing and staffing systems, not around any external deadline, which gave us more room than a financing-driven closing would have allowed, since neither side's lender was waiting on a fixed date that a short delay would put at risk.
3. Opened direct settlement discussions with Hanna's counsel. Rather than dispute whether the claim survived the defective release, which would have meant litigating a technical question with an uncertain outcome, we focused on negotiating a clean, properly executed resolution now that the authority gap made the original settlement's validity genuinely doubtful, since fighting over a technical defect would have cost more in time and fees than simply fixing it.
4. Restructured where the settlement obligation sat in the deal. We proposed, and the shell's board agreed, that the settlement payment to Hanna be funded from the shell's existing cash balance before the reverse takeover closed, so the liability was extinguished using money that predated Ama and Meron's businesses joining the structure, rather than the merged company's own funds, protecting the cash the new combined business would need for its first year of operations.
5. Negotiated a properly authorized release this time. The new settlement agreement was signed by a current, confirmed officer of the shell with documented authority, and we required Hanna's counsel to provide a full and final release naming both the shell and its successors, closing the exact gap that had left the first settlement ineffective and giving both founders a release they could actually rely on going forward.
6. Adjusted the purchase price allocation between Ama and Meron's companies to reflect the delay. The settlement and the six-week diligence extension it required shifted the deal's internal economics slightly, since Ama's business had been ready to close sooner; we built a small compensating adjustment into the share exchange ratio to reflect the extra carrying cost the delay imposed on her side.
7. Obtained a formal indemnity from the shell's remaining pre-transaction shareholders. As a backstop, we secured a limited indemnity covering any other undisclosed legacy liability that might surface after closing, funded from a small holdback of the shell's cash, so the merged company was not the only line of defence if another old claim appeared, and so the founders were not left exposed to a problem that predated their involvement entirely.
8. Reviewed the shell's remaining historical files for any other unreleased claims. Given that one settlement had failed silently for years without anyone noticing, we did not assume Hanna's claim was the only gap; we had the shell's remaining corporate and litigation records reviewed specifically for signature authority on every other past release, closing out that risk before closing rather than discovering a second version of the same problem after the listing had already gone public, when a new claim would have been far harder to contain quietly.

The outcome

The reverse takeover closed roughly seven weeks after the original target date, with Hanna's claim fully and properly released before the merged clinic group took over the shell's listing. The settlement payment came out of the shell's pre-existing cash balance rather than the combined company's operating funds, which limited the direct financial impact on Ama and Meron's business, though the seven-week delay pushed back the integration timeline they had built their staffing and billing plans around, meaning some scheduled system migrations had to be re-sequenced after closing rather than run in the run-up to it.

The outcome was not the clean, on-schedule listing either side had originally planned for, and it is worth being clear about who bore what. Ama absorbed a modest adjustment to her share of the combined company to reflect the delay's cost, a concession she accepted once it was clear the alternative was closing on schedule with an unresolved, and now clearly disputed, legal claim sitting inside the new public company. Meron's side bore the cost of the indemnity holdback, a small reduction in the cash the shell would otherwise have carried into the merged entity, money that effectively sat aside as insurance against a problem neither founder had created.

What the delay avoided was a public company entering its first months of operation defending litigation tied to a business it had never run, arising from a settlement that had failed for a reason neither founder had any part in. The combined clinic group listed with the legacy dispute fully closed rather than quietly following it into the new entity, and both founders have said since that they would rather have absorbed the seven-week delay than discover the same problem after the listing was already public, when investors and patients alike would have been watching. The indemnity holdback expired uneventfully a year later, with no further legacy claims surfacing from the shell's earlier history.

What you can learn from this